BR 1022
Latest Information Update: 14 Sep 2004
At a glance
- Originator Banyu
- Class Ischaemic heart disorder therapies
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Angina pectoris
Most Recent Events
- 31 Mar 2004 Banyu Pharmaceutical has become a wholly owned subsidiary of Merck & Co
- 06 Aug 1998 No-Development-Reported for Angina pectoris in Japan (Unknown route)
- 06 Nov 1996 New profile